Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Vildagliptin prevents the breakdown of GLP-1 and GIP by DPP-4, enabling these peptides to promote insulin release from beta cells and inhibit glucagon release from alpha cells within islets of Langerhans in the pancreas.